Development of a New Hybrid Biodegradable Drug-Eluting Stent for the Treatment of Peripheral Artery Disease

Table 2

Intravascular ultrasonographic findings from the maximum neointimal site at 4- and 8-week follow-ups.

	Group 1; ()	Group 2; ()	Group 3; ()	Group 4; ()
4-week follow-up
Stent area, mm^2					0.218
Lumen area, mm^2					0.037
Neointimal area, mm^2					0.196
Percentage of NIH (%)					0.072
8-week follow-up	()	()	()	()
Stent area, mm^2					0.248
Lumen area, mm^2					0.072
Neointimal area, mm^2					0.379
Percentage of NIH (%)					0.104

Group 1: bare-metal stent (BMS), group 2: drug-free hybrid stent, group 3: 50% PTX/PLGA (fast PTX-releasing form) hybrid stent, and group 4: 30% PTX/PLGA (slow PTX-releasing form) hybrid stent.
NIH: neointimal hyperplasia.